Works by Kueenburg, Elisabeth

Results: 10
    1

    P-203: EXCALIBER: a phase 3 study comparing iberdomide, daratumumab, and dexamethasone (IberDd) with daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed or refractory multiple myeloma.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S150, doi. 10.1016/S2152-2650(21)02330-2
    By:
    • Lonial, Sagar;
    • Berdeja, Jesus G.;
    • Dimopoulos, Meletios-Athanasios;
    • Jagannath, Sundar;
    • Knop, Stefan;
    • Hang Quach;
    • Rodríguez-Otero, Paula;
    • Richardson, Paul G.;
    • Sorrell, April;
    • Min Chen;
    • Kueenburg, Elisabeth;
    • Tuong Vi Nguyen;
    • Hong, Kevin;
    • Peluso, Teresa;
    • van de Donk, Niels W.C.J.
    Publication type:
    Article
    2

    OAB-013: Iberdomide (IBER) in combination with dexamethasone (DEX) and daratumumab (DARA), bortezomib (BORT), or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S9, doi. 10.1016/S2152-2650(21)02087-5
    By:
    • Lonial, Sagar;
    • Richardson, Paul G.;
    • Popat, Rakesh;
    • Stadtmauer, Edward A.;
    • Larsen, Jeremy T.;
    • Oriol, A.;
    • Knop, Stefan;
    • Jagannath, Sundar;
    • Cook, Gordon;
    • Badros, Ashraf Z.;
    • Rodríguez-Otero, Paula;
    • Siegel, David S.;
    • Tuong Vi Nguyen;
    • Micco, Antonia Di;
    • Amin, Alpesh;
    • Min Chen;
    • Kueenburg, Elisabeth;
    • van de Donk, Niels W.C.J.
    Publication type:
    Article
    3

    A Noninterventional, Observational, European Post-Authorization Safety Study of Patients With Relapsed/Refractory Multiple Myeloma Treated With Lenalidomide.

    Published in:
    2020
    By:
    • Gamberi, Barbara;
    • Berthou, Christian;
    • Hernandez, Miguel;
    • Semenzato, Gianpietro;
    • Tholouli, Eleni;
    • Hájek, Roman;
    • Caers, Jo;
    • Dimopoulos, Meletios;
    • Minnema, Monique C.;
    • Andreasson, Bjorn;
    • Parreira, Joana;
    • Crotty, Gerard;
    • Remes, Kari;
    • Kueenburg, Elisabeth;
    • Rosettani, Barbara;
    • Di Micco, Antonia;
    • Peters, Sarah;
    • Bacon, Pamela;
    • Blau, Igor Wolfgang
    Publication type:
    journal article
    4

    Pomalidomide and Dexamethasone Treatment for ≥ 1 Year in Renally Impaired Patients With Relapsed or Refractory Multiple Myeloma.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e284, doi. 10.1016/j.clml.2019.09.468
    By:
    • Weisel, Katja;
    • Dimopoulos, Meletios A.;
    • Cook, Mark;
    • Ramasamy, Karthik;
    • Rubia, Javier De La;
    • Ardizzoia, Antonio;
    • Krauth, Maria Theresa;
    • JACCARD, Arnaud;
    • Van de Donk, Niels;
    • Kueenburg, Elisabeth;
    • Di Micco, Antonia;
    • Rosettani, Barbara;
    • Atiba-Davies, Margaret;
    • Bacon, Pamela;
    • Sonneveld, Pieter
    Publication type:
    Article
    5

    European Post-Authorization Safety Study of Patients With Relapsed or Refractory Multiple Myeloma Treated With Pomalidomide in a Real-World Setting.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e256, doi. 10.1016/j.clml.2019.09.423
    By:
    • Gamberi, Barbara;
    • Albildgaard, Niels;
    • Vekemans, Marie-Christiane;
    • Payer, Angel Ramirez;
    • Kyriakou, Charalampia;
    • Di Raimondo, Francesco;
    • Kueenburg, Elisabeth;
    • Di Micco, Antonia;
    • Rosettani, Barbara;
    • Atiba-Davies, Margaret;
    • Bacon, Pamela;
    • Plesner, Torben
    Publication type:
    Article
    6
    7

    European Post-Approval Safety Study (EU Pass) of Relapsed/Refractory Multiple Myeloma (RRMM): Safety, Including Second Primary Malignancies, in a Large Cohort of Patients (Pts) Treated With Lenalidomide (LEN), Thalidomide (THAL), and Bortezomib (BORT).

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e65, doi. 10.1016/j.clml.2017.03.118
    By:
    • Gamberi, Barbara;
    • Hernandez, Miguel T.;
    • Berthou, Christian;
    • Tholouli, Eleni;
    • Zamagni, Elena;
    • Hajek, Roman;
    • Minnema, Monique;
    • Dimopoulos, Meletios Athanasios;
    • Caers, Jo;
    • Andersen, Niels Frost;
    • Andreasson, Bjorn;
    • Waage, Anders;
    • Crotty, Gerard;
    • Kueenburg, Elisabeth;
    • Rosettani, Barbara;
    • Di Micco, Antonio;
    • Bacon, Pamela;
    • Blau, Igor Wolfgang
    Publication type:
    Article
    8

    European Post-Approval Safety Study (EU Pass) of Relapsed/Refractory Multiple Myeloma (RRMM): Safety In Patients (Pts) Treated With Pomalidomide (POM).

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e62, doi. 10.1016/j.clml.2017.03.113
    By:
    • Di Raimondo, Francesco;
    • Kyriakou, Charalampia;
    • Schmidt-Hieber, Martin;
    • Vekemans, Marie-Christiane;
    • Payer, Angel Ramirez;
    • Bentsen, Pal Tore;
    • Lauri, Birgitta;
    • Kueenburg, Elisabeth;
    • Atiba-Davies, Margaret;
    • Lersch, Frederik;
    • Rosettani, Barbara;
    • Bacon, Pamela;
    • Plesner, Torben
    Publication type:
    Article
    9

    Phase 2 Multicenter Study of Pomalidomide (POM) Plus Low-Dose Dexamethasone (LoDEX) in Patients (Pts) With Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment (RI): An Updated Safety Analysis.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e145, doi. 10.1016/j.clml.2017.03.261
    By:
    • Weisel, Katja;
    • Dimopoulos, Meletios Athanasios;
    • Van de Donk, Niels;
    • Ramasamy, Karthik;
    • Gamberi, Barbara;
    • Streetly, Matthew;
    • Offidani, Massimo;
    • Bridoux, Frank;
    • Rubia, Javier de la;
    • Kueenburg, Elisabeth;
    • Collins, Shona;
    • Lersch, Frederik;
    • Rosettani, Barbara;
    • Bacon, Pamela;
    • Sonneveld, Pieter
    Publication type:
    Article
    10